North of England evidence-based guideline development project: Summary version of guidelines for the choice of antidepressants for depression in primary care

Family Practice

Volumn 16, Issue 2, 1999, Pages 103-111

  Eccles, Martin ^a   Freemantle, Nick ^a   Mason, James ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anti depressants; Depression; Guidelines

Indexed keywords

AMINEPTINE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LOFEPRAMINE; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG INTOXICATION; EVIDENCE BASED MEDICINE; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; REVIEW; RISK ASSESSMENT; UNITED KINGDOM;

ANTIDEPRESSIVE AGENTS; DEPRESSION; ENGLAND; EVIDENCE-BASED MEDICINE; HUMANS; PRIMARY HEALTH CARE;

EID: 0032985451     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: 10.1093/fampra/16.2.103     Document Type: Review

References (138)

1. [BNP] British National Formulary Number 32 (September 1996). London: The British Medical Association and the Royal Pharmaceutical Society of Great Britain, 1996.
2. North of England Antidepressant Guideline Development Group. Evidence Based Guideline for the choice of antidepressants for depression in primary care. Newcastle upon-Tyne: Centre for Health Services Research, 1997.
3. Eccles M, Freemantle N, Mason J. Methods of developing guidelines for efficient drug use in primary care: North of England Evidence Based Guidelines Development Project. Submitted for publication.
4. McCormick A, Fleming D, Charlton J. Morbidity Statistics in General Practice: Fourth National Study 1991-1992. Series MB5 No 3. London: HMSO, 1995.
5. Goldberg DP, Huxley P. Common mental disorders. London: Routledge, 1992.
6. Ahlfors UG, Elovaara S, Harma P et al. Clinical multicentre study of citalopram compared double-blindly with mianserin in depressed patients in Finland. Nord Psykiatr Tidsskr 1988; 42: 201-210.
7. Anon. Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology 1986; 90:131-138.
8. Bouchard JM, Delaunay J, Delisle JP et al. Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand 1987; 76:583-592.
9. De Wilde J, Mertens C, Overo KF, Peterson HEH. Citalopram versus mainserin: a controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 1985; 72:89-96.
10. Gravem A, Amthor KF, Astrup C et al. A double-blind comparison of citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 1987; 75:478-486.
11. Rosenberg C, Damsbo N, Fuglum E, Jacobsen LV, Horsgard S. Citalopram and imipramine in the treatment of depressive patients in general practice. A Nordic multicentre clinical study. lut Clin Psychopharmacol 1994; 9 (Suppl 1): 41-48.
12. Shaw DM, Thomas DR, Briscoe MH et al. A comparison of the antidepressant action of citalopram and amitriptyline. BrJ Psychiatr 1986;149:515-517.
13. Timmerman L, de Beurs P, Tan BK et al. A double-blind comparative clinical trial of citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 1987; 2:239-253.
14. Anon. A double-blind multi-centre trial of fluoxetine and dothiepin in major depressive illness. South Wales Antidepressant Drug Trial Group. Int Clin Psychopharmacol 1988; 3:75-81.
15. Beasley CM Jr, Dornseif BE, Pultz JA, Bosomworth JC, Sayler ME. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52:294-299.
16. Beasley CM Jr, Holman SL, Potvin JH. Fluoxetine compared with imipramine in the treatment of inpatient depression. A multicenter trial. Ann Clin Psychiatry 1993a; 5:199-207.
17. Beasley CM Jr, Sayler ME, Potvin JH. Fluoxetine versus amitriptyline in the treatment of major depression: a multicenter trial. Int din Psychopharmacol 1993b; 8:143-149.
18. Besancon G, Cousin R, Guitton B, Lavergne F. [Double-blind study of mianserin and fluoxetine in ambulatory therapy of depressed patients]. [French] OT-Etude en double aveugle de la mianserine et de la fluoxetine chez des patients deprimes traites en ambulatoire. Encephale 1993; 19:341-345.
19. Bowden CL, Schatzberg AF, Rosenbaum A et al. Fluoxetine and desipramine in major depressive disorder. J Clin Psychopharmacol 1993;13:305-311.
20. Bremner JD. Fluoxetine in depressed patients: a comparison with imipramine. J Clin Psychiatry 1984; 45:414-419.
21. Byerley WF, Reimherr FW, Wood DR, Grosser BI. Fluoxetine, a selective serotonin uptake inhibitor, for the treatment of outpatients with major depression. J Clin Psychopharmacol 1988; 8:112-115.
22. Cohn JB, Wilcox C. Paroxetine in major depression: a double-blind trial with imipramine and placebo. J Clin Psychiatry 1992; 53 (Suppl 2): 52-56.
23. Cohn JB, Wilcox C. A comparison of fluoxetine, imipramine and placebo in patients with major depressive disorders. J Clin Psychiatr 1985; 46:26-31.
24. Cohn JB, Collins G, Ashbrook E, Wernicke JE A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989; 4: 313-322.
25. Corne SJ, Hall JR. A double-blind comparative study of fluoxetine and dothiepin in the treatment of depression in general practice. Int Clin Psychopharmacol 1989; 4:245-254.
26. Dalery J, Rochat C, Peyron E, Bernard G. [Comparative study of the efficacy and acceptability "of amineptine and fluoxetine in patients with major depression]. [French] OT-Etude comparative de l'efficacite et de l'acceptabilite de l'amineptine et de la fluoxetine chez des patients depressifs majeurs. Encephale 1992; 18:257-262.
27. de Jonghe F, Ravelli DP, Tbynman-Qua H. A randomized, doubleblind study of fluoxetine and maprotiline in the treatment of major depression. Pharmacopsychiatry 1991a; 24:62-67.
28. Dowling B, Webb MGT, Malpin CM, Sangiwa MGH. Fluoxetine: a comparative study with dothiepin. Irish J Psychiatr 1990; 11: 3-7.
29. Fabre LF, Scharf MB, Itil TM. Comparative efficacy and safety of nortriptyline and fluoxetine in the treatment of major depression: a clinical study. J Clin Psychiatr 1991; 52 (SuppI): 62-67.
30. Falk WE, Rosenbaum JF, Otto MW, Zusky PM, Weilburg JB, Nixon RA. Fluoxetine versus trazodone in depressed geriatric patients. J Geriatr Psychiatry Neural 1989; 2:208-214.
31. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psychiatr 1985a; 46:20-25.
32. Feighner JP, Boyer WF, Merideth CH, Hendrickson GG. A doubleblind comparison of fluoxetine, imipramine and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989a; 4:127-134.
33. Ferreri M. Fluoxetine versus amineptine in the treatment of outpatients with major depressive disorders. Int Clin Psychopharmacol 1989; 4 (Suppl 1): 97-101.
34. Fudge JL, Perry PJ, Garvey MJ, Kelly MW. A comparison of the effect of fluoxetine and trazodone on the cognitive functioning of depressed outpatients. J Affect Disord 1990; 18:275-280.
35. Gattaz WF, Vogel P, Kick H, Kohnen R. Moclobemide versus fluoxetine in the treatment of inpatients with major depression. J Clin Psychopharmacol 1995; 15 (4, Suppl 2): 355-105.
36. Geerts S, Bruynooghe F, De Cuyper H, Demeulemeester F, Haazen L. Moclobemide versus fluoxetine for major depressive episodes. Clin Neuropharmacol 1994; 17 (Suppl 1): S50-57.
37. Ginestet D. Fluoxetine in endogenous depression and melancholia versus clomipramine. Int Clin Psychopharmacol 1989; 4 (Suppl 1): 37-40.
38. Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G. A multicentre double-blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness. Aust N Z J Psychiatr 1993; 27:49-55.
39. Keegan D, Bowen RC, Blackshaw S et al. A comparison of fluoxetine and amitriptyline in the treatment of major depression. Int Clin Psychopharmacol 1991; 6:117-124.
40. Kerkhofs M, Rielaert C, de Maertelaer V, Linkowski P, Czarka M, Mendlewicz J. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. Int Clin Psychopharmacol 1990; 5:253-260.
41. Kuha S, Mehtonen OP, Henttonen A, Naarala M. The efficacy of fluoxetine versus maprotiline in depressed patients and by dose. Nord Psykiatr Tidsskr 1991; 45:109-117.
42. La Pia S, Giorgio D, Ciriello R et al. Double-blind controlled study to evaluate the effectiveness and tolerability of fluoxetine versus mianserin in the treatment of depressive disorders among the elderly and their effects on cognitive behavioral parameters. New Trends Exp Clin Psychiatry 1992; 8:139-146
43. Laakmann G, Blaschke D, Engel R, Schwarz A. Fluoxetine vs amitriptyline in the treatment of depressed out-patients. Br J Psychiatr 1988; 153 (Suppl): 64-68.
44. Laakman G. Selective Re-uptake-hemmung und ihre Bedeutung fur die Depression. Springer Verlag (Monograph), 1991.
45. Levine S, Deo R, Mahadevan K. A comparative trial of a new antidepressant, fluoxetine. Int Clin Psychopharmacol 1989; 4 (Suppl 1): 41-45.
46. Lonnqvist J, Sintonen H, Syvalahti E et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994; 89: 363-369.
47. Manna V, Martucci N, Agnoli A. Double-blind controlled study on the clinical efficacy and safety of fluoxetine vs clomipramine in the treatment of major depressive disorders. Int Clin Psychopharmacol 1989; 4 (Suppl 1): 81-88.
48. Muijen M, Roy D, Silverstone T, Mehmet A, Christie M. A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 1988; 78:384-390.
49. Nielsen BM, Behnke K, Arup P et al. A comparison of fluoxetine and imipramine in the treatment of outpatients with major depressive disorder. Acta Psychiatr Scand 1993; 87:269-272.
50. Noguera R, Altuna R, Alvarez E, Ayuso JL, Casais L, Udina C. Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial. J Affect Disord 1991; 22:119-124.
51. Pakesch G, Dossenbach M. Depressive syndrome in a clinical trial with private practitioners. [German] OT-Wirkung und Sicherheit von Fluoxetin versus Clomipramin bei ambulanten Patienten mit einem depressiven Syndrom in einer klinischen Prufung bei niedergelassenen Arzten. Wiener Klinische Wochenschrift 1991; 103:175-182.
52. Peters UH, Lenhard P, Metz M. Therapy of depression in the psychiatrist's office-A double-blind multicenter study. Nervenheilkunde 1990; 9:28-31.
53. Poelinger W, Haber H. Fluoxetine 40 mg vs maprotiline 75 mg in the treatment of out-patients with depressive disorders. Int Clin Psychopharmacol 1989; 4 (Suppl 1): 47-50.
54. Remick RA, Keller FD, Gibson RE, Carter D. A comparison between fluoxetine and doxepin in depressed patients. Curr Ther Res Clin Exp 1989; 46:842-848.
55. Remick RA, Claman J, Reesal R et al. Comparison of fluoxetine and desipramine in depressed outpatients. Curr Ther Res Clin Exp 1993; 53:457-465.
56. Reynaert C, Parent M, Mirel J, Janne P, Haazen L. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology 1995; 118:183-187.
57. Robertson MM, Abou-Saleh MT, Harrison DA et al. A doubleblind controlled comparison of fluoxetine and lofepramine in major depressive illness. J Psychopharmacol 1994; 8:98-103.
58. Ropert R. Fluoxetine versus clomipramine in major depressive disorders. Int Clin Psychopharmacol 1989; 4 (Suppl 1): 89-95.
59. Stark P, Hardison CD. A review of multicenter controlled studies of fluoxetine vs imipramine and placebo in out patients with major depressive disorder. J Clin Psychiatr 1985; 46:53-58.
60. Stratta P, Bolino F, Cupillari M, Casacchia M. A double-blind parallel study comparing fluoxetine with imipramine in the treatment of atypical depression. Int Clin Psychopharmacol 1991;6:193-196.
61. Tapani TA, Lehtinen W. A double-blind parallel study to compare fluoxetine with doxepin in the treatment of major depressive disorders. Int J Psychopharmacol 1989; 4 (Suppl 1): 51-56.
62. Tollefson GD, Greist JH, Jefferson JW et al. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine. J Clin Psychopharmacol 1994; 14:385-391.
63. Upward JW, Edwards JG, Goldie A, Waller DG. Comparative effects of fluoxetine and amitriptyline on cardiac function. Br J Clin Pharmacol 1988; 26:399-402.
64. Williams R, Edwards RA, Newburn GM, Mullen R, Menkes DB, Segkar C. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 1993; 7:155-158.
65. Young JP, Coleman A, Lader MH. A controlled comparison of fluoxetine and amitriptyline in depressed out-patients. Br J Psychiatr 1987; 151:337-340.
66. Amin MM, Anath JV, Coleman BS et al. Fluvoxamine; antidepressant effects confirmed in a placebo controlled international study. Clin Neiiropharmacol 1984; 7:580-581.
67. Amore M, Bellini M, Berardi D et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Curr Ther Res Clin Exp 1989; 46:815-820.
68. Barrelet L, Blajev B, Bolzani L et al. Etude multicentrique comparant l'efficacite et la tolerance du moclobemide et de la fluvoxamine chez des patients hospitalises et ambulatoires presentant un episode depressif majeur. Schweiz Rundsch Med Prax 1991; 80:524-528.
69. Bocksberger JP, Gachoud JP, Richard J, Dick P. Comparison of the efficacy of moclobemide and fluvoxamine in elderly patients with a severe depressive episode. Eur Psychiatry 1993; 8:319-324.
70. Bougerol T, Uchida C, Gachoud JP, Kohler M, Mikkelsen H. Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial. Psychopharmacology 1992; 106 (SuppI): S102-108.
71. Bramanti P, Ricci RM, Roncari R et al. An Italian multicenter experience with fluvoxamine, a new antidepressant drug, versus imipramine. Curr Ther Res Clin Exp 1988; 43:718-725.
72. de Jonghe F, Swinkels J, Tuynman-Qua H. Randomized doubleblind study of fluvoxamine and maprotiline in treatment of depression. Pharmacopsychiatry 1991b; 24:21-27.
73. De Wilde JE, Mertens C, Walekin JS. Clinical trials of fluvoxamine vs chlorimipramine with single and three times daily dosing. BrJ Clin Pharmacol 1983; 15:427-431.
74. Dick P, Ferro E. A double-blind comparative study of the clinical efficacy of fluvoxamine and chlorimipramine. Br J Clin Pharmacol 1983; 15: 419s-425s.
75. Dominguez RA, Goldstein BJ, Jacobsen AF, Steinbook RM. A double-blind controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatr 1985; 46:84-87.
76. Gonella G, Baignoli G, Ecari U. Fluvoxamine and imipramine in the treatment of depressive patients: a double-blind controlled study. Curr Med Res Opin 1990; 12:177-184.
77. Guelfi JD, Dreyfus JF, Pichot P, GEPECP. A double-blind placebo controlled clinical trial comparing fluvoxamine with imipramine. Br J Clin Pharmacol 1983; 15:411s-417s.
78. Harris B, Szulecka TK, Anstee JA. Fluvoxamine versus amitriptyline in depressed hospital out patients: a multicentre doubleblind comparative trial. BrJ Clin Res 1991; 2:89-99.
79. Itil TM, Shrivastava RK, Mukherjee S, Coleman BS, Michael ST. A double-blind placebo-controlled study of fluvoxamine and imipramine in out patients with primary depression. BrJ Clin Pharmacol 1983; 15:433s-438s
80. Kasper S, Voll G, Vieira A, Kick H. Response to total sleep deprivation before and during treatment with fluvoxamine or maprotiline in patients with major depression-results of a double-blind study. Pharmacopsychiatry 1990; 23:135-142.
81. Klok CJ, Brouwer GJ, Van Praag HM, Doogan D. Flovoxamine and clomipramine in depressed patients: a double-blind clinical study. Acta Psychiatr Scand 1981; 64:1-11.
82. Lapierre YD, Browne M, Horn E et al. Treatment of major affective disorder with fluvoxamine. J Clin Psychiatr 1987; 48:65-68.
83. Lydiard RB, Laird LK, Morton WA Jr et al. Fluvoxamine, imipramine, and placebo in the treatment of depressed outpatients: effects on depression. Psychopharmacol Bull 1989; 25: 68-70.
84. March JS, Kobak KA, Jefferson JW, Mazza J, Greist JH. A doubleblind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. J Clin Psychiatr 1990; 51:200-202.
85. Mullin JM, Pandita-Gunawardena VR, Whitehead AM. A doubleblind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. BrJ Clin Pract 1988; 42:51-55.
86. Nathan RS, Perel JM, Pollack BG, Kupfer DJ. The role of neuropharmacologic selectivity in antidepressant action: fluvoxamine versus desipramine. J Clin Psychiatr 1990; 51:367-372.
87. Norton KRW, Sireling LI, Bhat AV, Rao B, Paykel ES. A doubleblind comparison of fluvoxamine, imipramine and placebo in depressed patients. J Affect Disord 1984; 7:297-308.
88. Ottevanger EA. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Encephale 1995; 21:317-321.
89. Ferez A, Ashford JJ. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Curr Med Res Opin 1990; 12:234-241.
90. Phanjoo AL, Wonnacott S, Hodgson A. Double-blind comparative multicentre study of fluvoxamine and mianserin in the treatment of major depressive episode in elderly people. Acta Psychiatr Scand 1991; 83:476-479.
91. Rahman MK, Aktar MJ, Salva NC, Sharma RR, Kellett JM, Ashford JJ. A double-blind randomised comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. BrJ Clin Pract 1991; 4:255-258.
92. Remick RA, Reesal R, Oakander M et al. Comparison of fluvoxamine and amitriptyline in depressed outpatients. Curr Ther Res Clin Exp 1994; 55:243-250.
93. Roth D, Mattes J, Sheehan KH, Sheehan DV. A .double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. Prog Neuropsychopharmacol Biol Psychiatr 1990; 14:929-939.
94. Ansseau M, Darimont P, Lecoq A et al. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology 1994; 115:254-260.
95. Feighner JP, Pambakian R, Fowler RC, Boyer WF, D'Amico MF. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25:219-221.
96. Fontaine R, Ontiveros A, Elie R et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatr 1994; 55:234-241.
97. Rickeis K, Schweizer E, Clary C, Fox I, Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. BrJ Psychiatr 1994; 164:802-805.
98. Anon. Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. J Affect Disord 1990; 18:289-299.
99. Arminen SL, Ikonen U, Pulkkinen M et al. Paroxetine and imipramine: A 12-week, double-blind multicentre study in hospitalized depressed patients. Nord J Psychiatry 1992; 46 (Suppl): 27-31.
100. Bascara L. A double-blind study to compare the effectiveness and tolerability of paroxetine and amitriptyline in depressed patients. Acta Psychiatr Scand 1989; 350 (Suppl): 141-142.
101. Battegay R, Hager M, Rauchfleisch U. Double-blind comparative study of paroxetine and amitriptyline in depressed patients of a university psychiatric out-patient clinic (pilot study). Neuropsychobiology 1985; 13:31-37.
102. Cohn JB, Crowder JE, Wilcox CS, Ryan PJ. A placebo- and imipramine-controlled study of paroxetine. Psychopharmacol Bull 1990a; 26:185-189.
103. Dorman T. Sleep and paroxetine: a comparison with mamserin in elderly depressed patients. Int Clin Psychopharmacol 1992; 6 (Suppl 4): 53-58.
104. Feighner JP, Cohn JB, Fabre LF Jr et al. A study comparing paroxetine placebo and imipramine in depressed patients. J Affect Disord 1993; 28:71-79.
105. Geretsegger C, Stuppaeck CH, Mair M, Platz T, Fartacek R, Heim M. Multicenter double-blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology 1995; 119:277-281.
106. Guillibert E, Pelicier Y, Archambault JC et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand 1989; 350 (Suppl): 132-134.
107. Hutchinson DR, Tong S, Moon CA, Vince M, Clarke A. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992; 6 (Suppl 4): 43-51
108. Kuhs H, Rudolf GA. A double-blind study of the comparative antidepressant effect of paroxetine and amitriptyline. Acta Psychiatr Scand 1989; 350 (Suppl): 145-146.
109. Laursen AI, Mildcelson PL, Rasmussen S, le Fevre Honore P. Paroxetine in the treatment of depression a randomised comparison with amitriptyline. Acta Psychiatr Scand 1985; 71:249-255.
110. Mertens C, Pintens H. Paroxetine in the treatment of depression. A double-blind multicenter study versus mianserin. Acta Psychiatr Scand 1988; 77:683-688.
111. Moller HJ, Berzewski H, Eckmann F et al. Double-blind multicenter study of paroxetine and amitriptyline in depressed inpatients. Pharmacopsychiatry 1993; 26:75-78.
112. Nielsen OA, Morsing I, Petersen JS et al. Paroxetine and imipramine treatment of depressive, patients in a controlled multicentre study with plasma amino acid measurements. Acta Psychiatr Scand 1991; 84:233-241.
113. Ohrberg S, Christiansen PE, Severin B et al. Paroxetine and imipramine in the treatment of depressive patients in psychiatric practice. Acta Psychiatr Scand 1992; 86:437-444.
114. Pelicier Y, Schaeffer P. [Multicenter double-blind study comparing the efficacy and tolerance of paroxetine and clomipramine in reactive depression in the elderly patient]. [French] OT -Etude multicentrique en double aveugle comparant l'efficacite et la tolerance de la paroxetine et de la clomipramine dans la depression reactionnelle du sujet age. Encephale 1993; 19: 257-261.
115. Peselow ED, Rlippi AM, Goodnick P, Barouche F, Fieve RR. The short- and long-term efficacy of paroxetine HC1: A. Data from a 6-week double-blind parallel design trial vs. imipramine and placebo. Psychopharmacol Bull 1989; 25:267-271.
116. Ravindran AV, Judge R, Hunter BN, Bray J, Morton NH. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. J Clin Psychiatr 1997; 58:112-118.
117. Shillingford JS, Hindmarch I, Clarke A, Vmce Ml A double-blind comparison of paroxetine and dothiepin on efficacy and tolerabihty in depressed community patients. Presented at the Collegium Internationale Neuro-Psychopharmacologium Congress, Kyoto, Japan 1990.
118. Staner L, Kerkhofs M, Detroux D, Leyman S, Linkowski P, Mendlewicz J. Acute, subchronic and withdrawal sleep EEG changes during treatment with paroxetine and amitriptyline: a double-blind randomized trial in major depression. Sleep 1995; 18:470-477.
119. Stott PC, Blagden MD, Aitken CA. Depression and associated anxiety in primary care: A double-blind comparison of paroxetine and amitriptyline. Eur Neuropsychopharmacol 1993:3:324-325.
120. Stuppaeck CH, Geretsegger C, Whitworth AB et al. A multicenter double-blind trial of paroxetine versus amitriptyline in depressed inpatients. J Clin Psychopharmacol 1994; 14: 241-246.
121. Bersani G, Rapisarda V, Ciani N, Bertolino A, Sorge G. A doubleblind comparative study of sertraline and amitriptyline in outpatients with major depressive episodes. Hum Psychopharmacol 1994; 9:63-68.
122. Cohn CK, Shrivastava R, Mendels J et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatr 1990; 51 (Suppl B): 28-33.
123. Moon CAL, Jago LW, Wood K, Doogan DP. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice. J Psychopharmacol 1994; 8:171-176.
124. Ravindran AV, Teehan MD, Bakish D et al. The impact of sertraline, desipramine, and placebo on psychomotor functioning in depression. Hum Psychopharmacol 1995; 10: 273-281.
125. Reimherr FW, Chouinard G, Cohn CK et al. Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. J Clin Psychiatr 1990; 51 (Suppl B): 18-27.
126. Thompson C. Sertraline in a primary care setting. In Racagni G (ed.). Biological Psychiatry. Amsterdam: Eisevier, 1991: 863-865.
127. Benkert O, Grunder G, Wetzel H, Hackett D. A randomized double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psych Res 1996; 30:441-451.
128. Cunningham LA, Borison RL, Carman JS et al. A comparison of venlafaxine, trazodone, and placebo in major depression [published erratum appears in J Clin Psychopharmacol 1994; 14:292]. J Clin Psychopharmacol 1994; 14(2): 99-106.
129. Mahapatra, van der Veer JK, Hackett D. A randomized, doubleblind, parallel group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Unpublished study (provided by Wyeth), 1996.
130. Schweizer E, Feighner J, Mandos LA, Rickeis K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatr 1994; 55: 104-108.
131. Shrivastava RK, Cohn C, Crowder J et al. Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatients with major depression. J Clin Psychopharmacol 1994; 14:322-329.
132. Simon GE, Vonkorff M, Heilingenstein JH et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA 1996; 275:1897-1902.
133. Freemantle N, Drummond MF. Should clinical trials with concurrent economic analyses be blinded? JAMA 1997; 277: 63-64.
134. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost effectiveness of pharmacological treatment. BrJ Psych 1994; 164:665-673.
135. Freemantle N, Maynard A. Something rotten in the state of clinical and economic analyses. Health Economics 1994; 3:63-67.
136. Jönsson B, Bebbington P. Economics of treatment of depression [authors' reply]. BrJ Psychiatr 1995; 166:398-399.
137. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. BrJ Psychiatr 1997; 170:257-263.
138. Mason JM. The Generalisability of Pharmacoeconomic Studies. Pharmacoeconomics 1997; in press.